A Class Of Drugs Called PARP Inhibitors Has Shown Great Promise In Treating Cancer
PARP Inhibitor are a class of drugs that have shown tremendous promise in the treatment of certain types of cancer. These drugs work by blocking the activity of an enzyme called poly ADP-ribose polymerase (PARP), which plays a critical role in repairing damaged DNA. By inhibiting PARP, these drugs can cause cancer cells to die.
ADP-ribose polymerase inhibitors are particularly effective in the treatment of cancers that are caused by mutations in genes that are involved in DNA repair, such as BRCA1 and BRCA2. These mutations can cause cancer cells to become more dependent on PARP for DNA repair, which makes them more vulnerable to ADP-ribose polymerase inhibitors.
The inhibitors of PARP Inhibitor Market was estimated at US$ 887.7 million in 2018 and is anticipated to grow at a CAGR of 32.4% during the projected period (2019–2027).
The first ADP-ribose polymerase inhibitor to be approved by the U.S. Food and Drug Administration (FDA) was olaparib (Lynparza), which was approved in 2014 for the treatment of ovarian cancer. Since then, several other ADP-ribose polymerase inhibitors have been approved for the treatment of ovarian, breast, and pancreatic cancer.
Ovarian Cancer
PARP Inhibitor have shown particular promise in the treatment of ovarian cancer, which is often difficult to treat and has a high mortality rate. In clinical trials, ADP-ribose polymerase inhibitors have been shown to improve progression-free survival (the length of time during which a patient’s cancer does not grow) and overall survival in women with ovarian cancer.
In addition to olaparib, other ADP-ribose polymerase ADP-ribose polymerase inhibitors that have been approved for the treatment of ovarian cancer include niraparib (Zejula) and rucaparib (Rubraca). These drugs are typically used in patients who have received multiple lines of chemotherapy and have a mutation in BRCA1 or BRCA2 or other genes involved in DNA repair.
Important immune checkpoint inhibitors (ICIs), PD-1 and PD-L1 Inhibitor are utilised as first-line therapies for a variety of cancers.
Breast Cancer
ADP-ribose polymerase inhibitors have also shown promise in the treatment of breast cancer, particularly in patients with mutations in BRCA1 or BRCA2. In clinical trials, ADP-ribose polymerase inhibitors have been shown to improve progression-free survival in patients with metastatic breast cancer.
The PARP Inhibitor talazoparib (Talzenna) was approved by the FDA in 2018 for the treatment of HER2-negative, locally advanced or metastatic breast cancer in patients with a germline BRCA1 or BRCA2 mutation. Olaparib has also been approved for the treatment of breast cancer in patients with a BRCA1 or BRCA2 mutation.

Comments
Post a Comment